INDIAGLYCO2023-10-012023-12-31 INDIAGLYCO2023-10-012023-12-31 INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses03Member INDIAGLYCO2023-12-31 INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets03Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member INDIAGLYCO2023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member INDIAGLYCO2023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member INDIAGLYCO2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member INDIAGLYCO2023-12-31in-bse-fin:OneReportableSegmentLiabilities03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500201 INDIAGLYCO NOTLISTED India Glycols Limited Equity 2023-04-01 2024-03-31 2024-02-02 2024-01-25 INR Crores Third quarter 15:54:00 17:04:00 2024-02-02 2024-02-02 Not applicable Multi segment 2023-10-01 2023-12-31 Unaudited Consolidated 21189400000.00 45500000.00 21234900000.00 5159600000.00 1141600000.00 -125500000.00 274400000.00 314100000.00 262400000.00 13716700000.00 20743300000.00 491600000.00 0.00 491600000.00 55700000.00 66900000.00 122600000.00 0.00 369000000.00 0.00 0.00 0.00 47300000.00 416300000.00 5100000.00 421400000.00 416300000.00 0.00 421400000.00 0.00 309600000.00 10 13.45 13.45 0.00 0.00 13.45 13.45 Note on Financial Results At point no 26 Face value of equity share capital of Rs 10 is the Face value per equity share Multi segment 2023-04-01 2023-12-31 Unaudited Consolidated 58824600000.00 210800000.00 59035400000.00 13174600000.00 2061100000.00 -105000000.00 734300000.00 880400000.00 747300000.00 39981800000.00 57474500000.00 1560900000.00 0.00 1560900000.00 96800000.00 272500000.00 369300000.00 0.00 1191600000.00 0.00 0.00 0.00 116200000.00 1307800000.00 -500000.00 1307300000.00 1307800000.00 0.00 1307300000.00 0.00 309600000.00 10 42.24 42.24 0.00 0.00 42.24 42.24 Excise Duty 12147200000.00 Other Expenses 781700000.00 Power and Fuel 787800000.00 Excise Duty 35146300000.00 Other Expenses 2273500000.00 Power and Fuel 2562000000.00 Bio-based Specialities and Performance Chemicalst 6092700000.00 Ennature Biopharma 505900000.00 Potable Spirits 14590800000.00 Bio-based Specialities and Performance Chemicalst 15183200000.00 Ennature Biopharma 1494800000.00 Potable Spirits 42146600000.00 21189400000.00 58824600000.00 0.00 0.00 21189400000.00 58824600000.00 Bio-based Specialities and Performance Chemicalst 377600000.00 Ennature Biopharma 119800000.00 Potable Spirits 414400000.00 Bio-based Specialities and Performance Chemicalst 1208900000.00 Ennature Biopharma 316700000.00 Potable Spirits 1242500000.00 911800000.00 2768100000.00 314100000.00 880400000.00 58800000.00 Note for Segment results Since there is no option to fill Share of profit loss of Joint Venture in the utility the same is clubbed with Other unallocable Expenditure net off Unallocable income The actual figures Rs in Crore are as follows for Q3FY24 a Other unallocable Expenditure net off Unallocable income 10.61 b Share of profit loss of Joint Venture 4.73 for nine months ended FY24 a Other unallocable Expenditure net off Unallocable income 32.68 b Share of profit loss of Joint Venture 11.62 210600000.00 538900000.00 1677100000.00 Bio-based Specialities and Performance Chemicalst 38830000000.00 Ennature Biopharma 4156300000.00 Potable Spirits 3489600000.00 46475900000.00 5691700000.00 52167600000.00 Bio-based Specialities and Performance Chemicalst 11915600000.00 Ennature Biopharma 786000000.00 Potable Spirits 3419500000.00 16121100000.00 15957100000.00 32078200000.00 1700000.00 2400000.00 0.00 0.00 -3400000.00 2900000.00